About
RNAi
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapyNJ, NY, PA
Team (3)
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
11
As Collaborator
2
Total Enrollment
621
By Phase
PHASE2: 5PHASE1: 5PHASE1/PHASE2: 2
By Status
TERMINATED: 5COMPLETED: 4RECRUITING: 2WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06154278Collaborator
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
PHASE2Recruiting
10 participants
Started: Jul 25, 2024 · Completed: Jul 1, 2027
NCT06277037Lead Sponsor
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
N/ARecruiting
50 participants
Started: Jul 11, 2024 · Completed: Oct 30, 2029
NCT06245291Lead Sponsor
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
PHASE2Withdrawn
Started: May 1, 2024 · Completed: Aug 1, 2024
NCT05960240Lead Sponsor
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
PHASE1Active, not recruiting
128 participants
Started: Aug 30, 2023 · Completed: Apr 30, 2026
NCT04980482Lead Sponsor
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
PHASE2Completed
43 participants
Started: Oct 29, 2021 · Completed: May 21, 2025
Locations (1)
Headquarters
Warminster, PA, United States
Map
Loading map...